person · Reporting owner

Bodem Barbara W.

Disclosed activity across 8 companies

Tapewire entity: 41446
SEC CIK: 0001713893

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404	Director	June 02, 2026	June 04, 2026
DENTSPLY SIRONA Inc.XRAY · Entity 4448	Interim CFO	May 06, 2022	May 13, 2022
Enovis CORPENOV · Entity 4797	Director	May 19, 2026	May 22, 2026
INVACARE HOLDINGS CorpIVC · Entity 86444	Director	March 16, 2018	March 20, 2018
Option Care Health, Inc.OPCH · Entity 4126	Director	May 20, 2026	May 22, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BIOMARIN PHARMACEUTICAL INC

Report date June 02, 2026 · Filed June 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	21,045	Reported balance After 2026-06-02 transaction · row 1 1 source row Row 1 · 2026-06-02 · Grant · Acquired 7,490 · Balance 21,045 F1: Restricted stock units granted on June 2, 2026. Price not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock units granted on June 2, 2026. Price not applicable.

DENTSPLY SIRONA Inc.

Report date May 06, 2022 · Filed May 13, 2022

This filing explicitly reported no securities owned.

Enovis CORP

Report date May 19, 2026 · Filed May 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stock, par value $0.001SEC Table I · non-derivative	Direct	24,201	Reported balance After 2026-05-19 transaction · row 1 1 source row Row 1 · 2026-05-19 · Grant · Acquired 9,346 · Balance 24,201

INVACARE HOLDINGS Corp

Report date March 16, 2018 · Filed March 20, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	11,728	Reported balance After 2018-03-16 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2018-03-16 · Grant · Acquired 6,708 · Balance 11,728 F1: Restricted stock units granted pursuant to the Invacare Corporation 2013 Equity Compensation Plan in an exempt transaction under Rule 16b-3. These restricted stock units vest in full on May 15, 2019. F2: Includes 5,020 previously reported restricted stock units issued pursuant to the Invacare Corporation 2013 Equity Compensation Plan that vest in full on August 15, 2018.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock units granted pursuant to the Invacare Corporation 2013 Equity Compensation Plan in an exempt transaction under Rule 16b-3. These restricted stock units vest in full on May 15, 2019.

F2: Includes 5,020 previously reported restricted stock units issued pursuant to the Invacare Corporation 2013 Equity Compensation Plan that vest in full on August 15, 2018.

Option Care Health, Inc.

Report date May 20, 2026 · Filed May 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	21,087	Reported balance After 2026-05-20 transaction · row 1 1 source row Row 1 · 2026-05-20 · Grant · Acquired 8,997 · Balance 21,087 F1: The reporting person received an award of restricted stock units on May 20, 2026, which vest in full on May 20, 2027. The number of restricted stock units granted was calculated to reflect $200,000 of value based on the closing price of the issuer's common stock on May 20, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person received an award of restricted stock units on May 20, 2026, which vest in full on May 20, 2027. The number of restricted stock units granted was calculated to reflect $200,000 of value based on the closing price of the issuer's common stock on May 20, 2026.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Hill-Rom Holdings, Inc.

Report date December 13, 2021 · Filed December 15, 2021

Section 16 reporting ended · disclosed 2021-12-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2021-12-13 transaction · row 1 1 source row Row 1 · 2021-12-13 · Disposition to issuer · Disposed 14,039.759 · Balance 0 F1: Amount of securities beneficially owned at the end of the reporting period includes 718.759 shares held in the Hill-Rom Holdings, Inc. Employee Stock Purchase Plan. F2: Disposed of pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter (the "Merger Agreement") in exchange for a cash payment of $156.00 per share of common stock.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $98.76 · Expires 2028-12-03	Direct	Reported balance After 2021-12-13 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-12-13 · Disposition to issuer · Disposed 10,272 · Balance 0 F3: Pursuant to the Merger Agreement, these options, which provided for vesting in four equal installments beginning on December 3, 2019, were cancelled in exchange for a cash payment representing the difference between $156.00 and the exercise price of each share of underlying common stock.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $103.11 · Expires 2029-11-06	Direct	Reported balance After 2021-12-13 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-12-13 · Disposition to issuer · Disposed 15,491 · Balance 0 F4: Pursuant to the Merger Agreement, these options, which provided for vesting in four equal installments beginning on November 6, 2020, were cancelled in exchange for a cash payment representing the difference between $156.00 and the exercise price of each share of underlying common stock.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $94.14 · Expires 2030-11-11	Direct	Reported balance After 2021-12-13 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-12-13 · Disposition to issuer · Disposed 17,935 · Balance 0 F5: Pursuant to the Merger Agreement, these options, which provided for vesting in four equal installments beginning on November 11, 2021, were cancelled in exchange for a cash payment representing the difference between $156.00 and the exercise price of each share of underlying common stock.
Performance-Based Restricted Stock Units (11/06/2019)SEC Table II · derivative / convertible security	Direct	Reported balance After 2021-12-13 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-12-13 · Disposition to issuer · Disposed 7,452 · Balance 0 F6: Each performance-based restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F7: Pursuant to the Merger Agreement, these performance-based restricted stock units, which were granted November 6, 2019, were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock and applicable performance conditions were deemed to be achieved at 146.0% of the target performance level.
Performance-Based Restricted Stock Units (11/11/2020)SEC Table II · derivative / convertible security	Direct	Reported balance After 2021-12-13 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-12-13 · Disposition to issuer · Disposed 9,091 · Balance 0 F6: Each performance-based restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F8: Pursuant to the Merger Agreement, these performance-based restricted stock units, which were granted November 11, 2020, were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock and applicable performance conditions were deemed to be achieved at 187.5% of the target performance level.
Restricted Stock Units (11/06/2019)SEC Table II · derivative / convertible security	Direct	Reported balance After 2021-12-13 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-12-13 · Disposition to issuer · Disposed 1,253 · Balance 0 F9: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F10: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 7, 2020, were cancelled in exchange for a cash payment of $156.00 per unvested share of underlying common stock.
Restricted Stock Units (11/11/2020)SEC Table II · derivative / convertible security	Direct	Reported balance After 2021-12-13 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2021-12-13 · Disposition to issuer · Disposed 3,026 · Balance 0 F9: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F11: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 12, 2021, were cancelled in exchange for a cash payment of $156.00 per unvested share of underlying common stock.
Restricted Stock Units (11/10/2021)SEC Table II · derivative / convertible security	Direct	Reported balance After 2021-12-13 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2021-12-13 · Disposition to issuer · Disposed 13,951 · Balance 0 F9: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F12: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 11, 2022, were assumed by Baxter in the merger and converted into a number of restricted stock units granted by Baxter, that relate to shares of Baxter common stock, determined by multiplying the number of restricted stock units by the quotient obtained by dividing (A) 156.00 by (B) the average closing price, rounded down to the nearest cent, per share of Hill-Rom Holdings, Inc. common stock on the New York Stock Exchange for the consecutive period of ten (10) trading days immediately preceding (but not including) the last trading day prior to the closing date of the merger.

Filing footnotes · ownership attribution and instrument terms

F1: Amount of securities beneficially owned at the end of the reporting period includes 718.759 shares held in the Hill-Rom Holdings, Inc. Employee Stock Purchase Plan.

F2: Disposed of pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter (the "Merger Agreement") in exchange for a cash payment of $156.00 per share of common stock.

F3: Pursuant to the Merger Agreement, these options, which provided for vesting in four equal installments beginning on December 3, 2019, were cancelled in exchange for a cash payment representing the difference between $156.00 and the exercise price of each share of underlying common stock.

F4: Pursuant to the Merger Agreement, these options, which provided for vesting in four equal installments beginning on November 6, 2020, were cancelled in exchange for a cash payment representing the difference between $156.00 and the exercise price of each share of underlying common stock.

F5: Pursuant to the Merger Agreement, these options, which provided for vesting in four equal installments beginning on November 11, 2021, were cancelled in exchange for a cash payment representing the difference between $156.00 and the exercise price of each share of underlying common stock.

F6: Each performance-based restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock.

F7: Pursuant to the Merger Agreement, these performance-based restricted stock units, which were granted November 6, 2019, were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock and applicable performance conditions were deemed to be achieved at 146.0% of the target performance level.

F8: Pursuant to the Merger Agreement, these performance-based restricted stock units, which were granted November 11, 2020, were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock and applicable performance conditions were deemed to be achieved at 187.5% of the target performance level.

F9: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock.

F10: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 7, 2020, were cancelled in exchange for a cash payment of $156.00 per unvested share of underlying common stock.

F11: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 12, 2021, were cancelled in exchange for a cash payment of $156.00 per unvested share of underlying common stock.

F12: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 11, 2022, were assumed by Baxter in the merger and converted into a number of restricted stock units granted by Baxter, that relate to shares of Baxter common stock, determined by multiplying the number of restricted stock units by the quotient obtained by dividing (A) 156.00 by (B) the average closing price, rounded down to the nearest cent, per share of Hill-Rom Holdings, Inc. common stock on the New York Stock Exchange for the consecutive period of ten (10) trading days immediately preceding (but not including) the last trading day prior to the closing date of the merger.

Syneos Health, Inc.

Report date September 28, 2023 · Filed September 28, 2023

Section 16 reporting ended · disclosed 2023-09-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2023-09-28 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2023-09-28 · Disposition to issuer · Disposed 3,522 · Balance 4,863 F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes. Row 2 · 2023-09-28 · Disposition to issuer · Disposed 4,863 · Balance 0 F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes. F2: In accordance with the Merger Agreement, effective as of immediately prior to the effective time of the Merger (the "Effective Time") and as a result of the Merger each award of restricted stock units ("RSUs") and performance stock units ("PSUs") covering shares of common stock that is outstanding immediately prior to the Effective Time (other than certain specified RSU awards and PSU awards set forth in the disclosure schedules delivered in connection with the Merger Agreement (the "Specified Awards")) was cancelled and converted into a contingent right to receive an amount in cash (without interest) (a "Contingent Cash Award") equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award (with any performance based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance or based on the actual level of achievement of performance goals, F3: continued from previous footnote: in each case, as set forth in the applicable PSU award agreement). Each Contingent Cash Award will vest and become payable pursuant to the same time-vesting schedule applicable to the underlying RSU award or PSU award from which it was converted, as applicable (including any accelerated vesting terms and conditions), subject to the holder's continued employment with or service to Parent and its subsidiaries through the applicable vesting date; and each Specified Award that is outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest) equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award, subject to claw-back if the holder's employment is terminated by the Company for "cause" or by the holder without "good reason," in either case prior to the first anniversary of the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes.

F2: In accordance with the Merger Agreement, effective as of immediately prior to the effective time of the Merger (the "Effective Time") and as a result of the Merger each award of restricted stock units ("RSUs") and performance stock units ("PSUs") covering shares of common stock that is outstanding immediately prior to the Effective Time (other than certain specified RSU awards and PSU awards set forth in the disclosure schedules delivered in connection with the Merger Agreement (the "Specified Awards")) was cancelled and converted into a contingent right to receive an amount in cash (without interest) (a "Contingent Cash Award") equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award (with any performance based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance or based on the actual level of achievement of performance goals,

F3: continued from previous footnote: in each case, as set forth in the applicable PSU award agreement). Each Contingent Cash Award will vest and become payable pursuant to the same time-vesting schedule applicable to the underlying RSU award or PSU award from which it was converted, as applicable (including any accelerated vesting terms and conditions), subject to the holder's continued employment with or service to Parent and its subsidiaries through the applicable vesting date; and each Specified Award that is outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest) equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award, subject to claw-back if the holder's employment is terminated by the Company for "cause" or by the holder without "good reason," in either case prior to the first anniversary of the Effective Time.

Turning Point Therapeutics, Inc.

Report date August 17, 2022 · Filed August 17, 2022

Section 16 reporting ended · disclosed 2022-08-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $94.59 · Expires 2031-03-30	Direct	0	Reported balance After 2022-08-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-08-17 · Disposition to issuer · Disposed 14,995 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price equal to or greater than $76.00, was cancelled without any consideration in respect of such cancelled option.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger").

F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price equal to or greater than $76.00, was cancelled without any consideration in respect of such cancelled option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 02, 2026 Filed Jun 4, 2026 22:02 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	GrantCommon Stock	7,490	$0.00	$0.00	Disclosure SEC source: 0001628280-26-040907 · wk-form4_1780610567.xml · nonDerivative · entry 1 Bodem Barbara W. · CIK 0001713893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,045 F1 · price: Restricted stock units granted on June 2, 2026. Price not applicable. Read SEC document
May 20, 2026 Filed May 22, 2026 22:06 UTC	Option Care Health, Inc. OPCH · Entity 4126	GrantCommon Stock	8,997	$0.00	$0.00	Disclosure SEC source: 0001437749-26-018298 · rdgdoc.xml · nonDerivative · entry 1 Bodem Barbara W. · CIK 0001713893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,087 F1 · shares: The reporting person received an award of restricted stock units on May 20, 2026, which vest in full on May 20, 2027. The number of restricted stock units granted was calculated to reflect $200,000 of value based on the closing price of the issuer's common stock on May 20, 2026. Read SEC document
May 19, 2026 Filed May 22, 2026 00:30 UTC	Enovis CORP ENOV · Entity 4797	GrantCommon stock, par value $0.001	9,346	$0.00	$0.00	Disclosure SEC source: 0001193125-26-235176 · ownership.xml · nonDerivative · entry 1 Bodem Barbara W. · CIK 0001713893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,201 Read SEC document
May 21, 2025 Filed May 24, 2025 01:00 UTC	Enovis CORP ENOV · Entity 4797	GrantCommon stock, par value $0.001	6,598	$0.00	$0.00	Disclosure SEC source: 0000950170-25-077285 · ownership.xml · nonDerivative · entry 1 Bodem Barbara W. · CIK 0001713893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,855 Read SEC document
May 20, 2025 Filed May 22, 2025 20:51 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	GrantCommon Stock	6,650	$0.00	$0.00	Disclosure SEC source: 0001048477-25-000064 · wk-form4_1747947072.xml · nonDerivative · entry 1 Bodem Barbara W. · CIK 0001713893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,555 F1 · price: Restricted stock units granted on May 20, 2025. Price not applicable. F2 · balance_after: The Reporting Person's direct holdings have been adjusted by five shares to correct a previous clerical error. Read SEC document
May 14, 2025 Filed May 19, 2025 22:25 UTC	Option Care Health, Inc. OPCH · Entity 4126	GrantCommon Stock	5,034	$0.00	$0.00	Disclosure SEC source: 0001437749-25-017669 · rdgdoc.xml · nonDerivative · entry 1 Bodem Barbara W. · CIK 0001713893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,090 F1 · shares: The reporting person received an award of restricted stock units on May 14, 2025, which vest in equal installments on each of the first, second and third anniversaries of the grant date. The number of restricted stock units granted was calculated to reflect $160,000 of value based on the closing price of the issuer's common stock on May 14, 2025. Read SEC document
May 21, 2024 Filed May 23, 2024 21:08 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	GrantCommon Stock	4,720	$0.00	$0.00	Disclosure SEC source: 0001048477-24-000094 · wk-form4_1716498523.xml · nonDerivative · entry 1 Bodem Barbara W. · CIK 0001713893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,900 F1 · price: Restricted stock units granted on May 21, 2024. Price not applicable. Read SEC document
May 20, 2024 Filed May 23, 2024 00:00 UTC	Enovis CORP ENOV · Entity 4797	GrantCommon stock, par value $0.001	4,338	$0.00	$0.00	Disclosure SEC source: 0000950170-24-063717 · ownership.xml · nonDerivative · entry 1 Bodem Barbara W. · CIK 0001713893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,257 Read SEC document
May 15, 2024 Filed May 17, 2024 20:51 UTC	Option Care Health, Inc. OPCH · Entity 4126	GrantCommon Stock	5,325	$0.00	$0.00	Disclosure SEC source: 0001437749-24-017506 · rdgdoc.xml · nonDerivative · entry 1 Bodem Barbara W. · CIK 0001713893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,056 F1 · shares: The reporting person received an award of restricted stock units on May 15, 2024, which vest in equal installments on each of the first, second and third anniversaries of the grant date. The number of restricted stock units granted was calculated to reflect $160,000 of value based on the closing price of the issuer's common stock on May 15, 2024. Read SEC document
April 01, 2024 Filed Apr 3, 2024 22:13 UTC	Option Care Health, Inc. OPCH · Entity 4126	GrantCommon Stock	1,731	$0.00	$0.00	Disclosure SEC source: 0001437749-24-010937 · rdgdoc.xml · nonDerivative · entry 1 Bodem Barbara W. · CIK 0001713893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,731 Read SEC document
December 27, 2023 Filed Dec 28, 2023 18:18 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	GrantCommon Stock	2,180	$0.00	$0.00	Disclosure SEC source: 0001048477-23-000076 · wk-form4_1703787510.xml · nonDerivative · entry 1 Bodem Barbara W. · CIK 0001713893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,180 F1 · price: Restricted stock units granted on December 27, 2023. Price not applicable. Read SEC document
September 28, 2023 Filed Sep 28, 2023 17:05 UTC	Syneos Health, Inc. SYNH · Entity 109360	Disposition to issuerClass A Common Stock	4,863	$0.00	$0.00	Disclosure SEC source: 0001209191-23-050771 · doc4.xml · nonDerivative · entry 2 Bodem Barbara W. · CIK 0001713893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes. F2 · price: In accordance with the Merger Agreement, effective as of immediately prior to the effective time of the Merger (the "Effective Time") and as a result of the Merger each award of restricted stock units ("RSUs") and performance stock units ("PSUs") covering shares of common stock that is outstanding immediately prior to the Effective Time (other than certain specified RSU awards and PSU awards set forth in the disclosure schedules delivered in connection with the Merger Agreement (the "Specified Awards")) was cancelled and converted into a contingent right to receive an amount in cash (without interest) (a "Contingent Cash Award") equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award (with any performance based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance or based on the actual level of achievement of performance goals, F3 · price: continued from previous footnote: in each case, as set forth in the applicable PSU award agreement). Each Contingent Cash Award will vest and become payable pursuant to the same time-vesting schedule applicable to the underlying RSU award or PSU award from which it was converted, as applicable (including any accelerated vesting terms and conditions), subject to the holder's continued employment with or service to Parent and its subsidiaries through the applicable vesting date; and each Specified Award that is outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest) equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award, subject to claw-back if the holder's employment is terminated by the Company for "cause" or by the holder without "good reason," in either case prior to the first anniversary of the Effective Time. Read SEC document
September 28, 2023 Filed Sep 28, 2023 17:05 UTC	Syneos Health, Inc. SYNH · Entity 109360	Disposition to issuerClass A Common Stock	3,522	$43.00	$151,446.00	Disclosure SEC source: 0001209191-23-050771 · doc4.xml · nonDerivative · entry 1 Bodem Barbara W. · CIK 0001713893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,863 F1 · price: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes. Read SEC document
May 25, 2023 Filed May 30, 2023 17:12 UTC	Syneos Health, Inc. SYNH · Entity 109360	GrantClass A Common Stock	4,863	$0.00	$0.00	Disclosure SEC source: 0001209191-23-032938 · doc4.xml · nonDerivative · entry 1 Bodem Barbara W. · CIK 0001713893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,385 F1 · shares: Represents an award of restricted stock units that vests in full one year from the grant date, or, if earlier, the date of the 2024 annual meeting of stockholders but only to the extent the director is not re-elected as a non-employee director at such annual meeting, in each case, subject to continued service on the Issuer's Board of Directors. Read SEC document
May 16, 2023 Filed May 18, 2023 23:00 UTC	Enovis CORP ENOV · Entity 4797	GrantDirector stock option (right to buy) · Derivative	4,167	$0.00 Strike: $56.76	$0.00	Disclosure SEC source: 0001209191-23-030806 · doc4.xml · derivative · entry 2 Bodem Barbara W. · CIK 0001713893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,167 Underlying: Common stock, par value $0.001 · 4,167 shares Expires 2030-05-16 Read SEC document
May 16, 2023 Filed May 18, 2023 23:00 UTC	Enovis CORP ENOV · Entity 4797	GrantCommon stock, par value $0.001	1,875	$0.00	$0.00	Disclosure SEC source: 0001209191-23-030806 · doc4.xml · nonDerivative · entry 1 Bodem Barbara W. · CIK 0001713893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,919 Read SEC document
August 17, 2022 Filed Aug 17, 2022 16:37 UTC	Turning Point Therapeutics, Inc. TPTX · Entity 124461	Disposition to issuerStock Option (right to buy) · Derivative	14,995	Not disclosed Strike: $94.59	Not disclosed	Disclosure SEC source: 0001209191-22-046283 · doc4.xml · derivative · entry 1 Bodem Barbara W. · CIK 0001713893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,995 shares Expires 2031-03-30 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). F2 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price equal to or greater than $76.00, was cancelled without any consideration in respect of such cancelled option. F2 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price equal to or greater than $76.00, was cancelled without any consideration in respect of such cancelled option. Read SEC document
June 07, 2022 Filed Jun 9, 2022 23:00 UTC	Enovis CORP ENOV · Entity 4797	GrantDirector Stock Option (right to buy) · Derivative	3,464	$0.00 Strike: $67.28	$0.00	Disclosure SEC source: 0001209191-22-035602 · doc4.xml · derivative · entry 3 Bodem Barbara W. · CIK 0001713893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,464 Underlying: Common stock, par value $.001 · 3,464 shares Expires 2029-06-07 Read SEC document
June 07, 2022 Filed Jun 9, 2022 23:00 UTC	Enovis CORP ENOV · Entity 4797	GrantCommon stock, par value $.001	1,648	$0.00	$0.00	Disclosure SEC source: 0001209191-22-035602 · doc4.xml · nonDerivative · entry 2 Bodem Barbara W. · CIK 0001713893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,044 Read SEC document
June 07, 2022 Filed Jun 9, 2022 23:00 UTC	Enovis CORP ENOV · Entity 4797	GrantCommon stock, par value $.001	396	$0.00	$0.00	Disclosure SEC source: 0001209191-22-035602 · doc4.xml · nonDerivative · entry 1 Bodem Barbara W. · CIK 0001713893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396 Read SEC document
May 25, 2022 Filed May 27, 2022 17:54 UTC	Syneos Health, Inc. SYNH · Entity 109360	GrantClass A Common Stock	2,839	$0.00	$0.00	Disclosure SEC source: 0001209191-22-032701 · doc4.xml · nonDerivative · entry 1 Bodem Barbara W. · CIK 0001713893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,522 F1 · shares: Represents an award of restricted stock units that vests in full one year from the grant date, or, if earlier, the date of the next subsequent annual meeting following the grant date but only to the extent the director is not re-elected as a non-employee director at such annual meeting, in each case, subject to continued service on the Issuer's Board of Directors. Read SEC document
January 18, 2022 Filed Jan 20, 2022 17:08 UTC	Syneos Health, Inc. SYNH · Entity 109360	GrantClass A Common Stock	654	$0.00	$0.00	Disclosure SEC source: 0001209191-22-004090 · doc4.xml · nonDerivative · entry 1 Bodem Barbara W. · CIK 0001713893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 683 F1 · shares: Represents an award of restricted stock units which vests in full one year from the grant date, subject to continued service on the Issuer's Board of Directors or, if earlier, the date of the next subsequent annual meeting following the grant date but only to the extent the director is not re-elected as a non-employee director at such annual meeting. Read SEC document
December 13, 2021 Filed Dec 15, 2021 20:40 UTC	Hill-Rom Holdings, Inc. HRC · Entity 132395	Disposition to issuerRestricted Stock Units (11/10/2021) · Derivative	13,951	Not disclosed	Not disclosed	Disclosure SEC source: 0001214659-21-013211 · marketforms-54634.xml · derivative · entry 9 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,951 shares Expires not disclosed F9 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F12 · price: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 11, 2022, were assumed by Baxter in the merger and converted into a number of restricted stock units granted by Baxter, that relate to shares of Baxter common stock, determined by multiplying the number of restricted stock units by the quotient obtained by dividing (A) 156.00 by (B) the average closing price, rounded down to the nearest cent, per share of Hill-Rom Holdings, Inc. common stock on the New York Stock Exchange for the consecutive period of ten (10) trading days immediately preceding (but not including) the last trading day prior to the closing date of the merger. F12 · derivative.exercise_date: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 11, 2022, were assumed by Baxter in the merger and converted into a number of restricted stock units granted by Baxter, that relate to shares of Baxter common stock, determined by multiplying the number of restricted stock units by the quotient obtained by dividing (A) 156.00 by (B) the average closing price, rounded down to the nearest cent, per share of Hill-Rom Holdings, Inc. common stock on the New York Stock Exchange for the consecutive period of ten (10) trading days immediately preceding (but not including) the last trading day prior to the closing date of the merger. F12 · derivative.expiration_date: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 11, 2022, were assumed by Baxter in the merger and converted into a number of restricted stock units granted by Baxter, that relate to shares of Baxter common stock, determined by multiplying the number of restricted stock units by the quotient obtained by dividing (A) 156.00 by (B) the average closing price, rounded down to the nearest cent, per share of Hill-Rom Holdings, Inc. common stock on the New York Stock Exchange for the consecutive period of ten (10) trading days immediately preceding (but not including) the last trading day prior to the closing date of the merger. Read SEC document
December 13, 2021 Filed Dec 15, 2021 20:40 UTC	Hill-Rom Holdings, Inc. HRC · Entity 132395	Disposition to issuerRestricted Stock Units (11/11/2020) · Derivative	3,026	Not disclosed	Not disclosed	Disclosure SEC source: 0001214659-21-013211 · marketforms-54634.xml · derivative · entry 8 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,026 shares Expires not disclosed F9 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F11 · price: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 12, 2021, were cancelled in exchange for a cash payment of $156.00 per unvested share of underlying common stock. F11 · derivative.exercise_date: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 12, 2021, were cancelled in exchange for a cash payment of $156.00 per unvested share of underlying common stock. F11 · derivative.expiration_date: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 12, 2021, were cancelled in exchange for a cash payment of $156.00 per unvested share of underlying common stock. Read SEC document
December 13, 2021 Filed Dec 15, 2021 20:40 UTC	Hill-Rom Holdings, Inc. HRC · Entity 132395	Disposition to issuerRestricted Stock Units (11/06/2019) · Derivative	1,253	Not disclosed	Not disclosed	Disclosure SEC source: 0001214659-21-013211 · marketforms-54634.xml · derivative · entry 7 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,253 shares Expires not disclosed F9 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F10 · price: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 7, 2020, were cancelled in exchange for a cash payment of $156.00 per unvested share of underlying common stock. F10 · derivative.exercise_date: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 7, 2020, were cancelled in exchange for a cash payment of $156.00 per unvested share of underlying common stock. F10 · derivative.expiration_date: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 7, 2020, were cancelled in exchange for a cash payment of $156.00 per unvested share of underlying common stock. Read SEC document
December 13, 2021 Filed Dec 15, 2021 20:40 UTC	Hill-Rom Holdings, Inc. HRC · Entity 132395	Disposition to issuerPerformance-Based Restricted Stock Units (11/11/2020) · Derivative	9,091	Not disclosed	Not disclosed	Disclosure SEC source: 0001214659-21-013211 · marketforms-54634.xml · derivative · entry 6 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,091 shares Expires not disclosed F6 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F8 · price: Pursuant to the Merger Agreement, these performance-based restricted stock units, which were granted November 11, 2020, were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock and applicable performance conditions were deemed to be achieved at 187.5% of the target performance level. F8 · derivative.exercise_date: Pursuant to the Merger Agreement, these performance-based restricted stock units, which were granted November 11, 2020, were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock and applicable performance conditions were deemed to be achieved at 187.5% of the target performance level. F8 · derivative.expiration_date: Pursuant to the Merger Agreement, these performance-based restricted stock units, which were granted November 11, 2020, were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock and applicable performance conditions were deemed to be achieved at 187.5% of the target performance level. Read SEC document
December 13, 2021 Filed Dec 15, 2021 20:40 UTC	Hill-Rom Holdings, Inc. HRC · Entity 132395	Disposition to issuerPerformance-Based Restricted Stock Units (11/06/2019) · Derivative	7,452	Not disclosed	Not disclosed	Disclosure SEC source: 0001214659-21-013211 · marketforms-54634.xml · derivative · entry 5 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,452 shares Expires not disclosed F6 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F7 · price: Pursuant to the Merger Agreement, these performance-based restricted stock units, which were granted November 6, 2019, were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock and applicable performance conditions were deemed to be achieved at 146.0% of the target performance level. F7 · derivative.exercise_date: Pursuant to the Merger Agreement, these performance-based restricted stock units, which were granted November 6, 2019, were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock and applicable performance conditions were deemed to be achieved at 146.0% of the target performance level. F7 · derivative.expiration_date: Pursuant to the Merger Agreement, these performance-based restricted stock units, which were granted November 6, 2019, were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock and applicable performance conditions were deemed to be achieved at 146.0% of the target performance level. Read SEC document
December 13, 2021 Filed Dec 15, 2021 20:40 UTC	Hill-Rom Holdings, Inc. HRC · Entity 132395	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	17,935	$61.86 Strike: $94.14	$1,109,459.10	Disclosure SEC source: 0001214659-21-013211 · marketforms-54634.xml · derivative · entry 4 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,935 shares Expires 2030-11-11 F5 · price: Pursuant to the Merger Agreement, these options, which provided for vesting in four equal installments beginning on November 11, 2021, were cancelled in exchange for a cash payment representing the difference between $156.00 and the exercise price of each share of underlying common stock. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, these options, which provided for vesting in four equal installments beginning on November 11, 2021, were cancelled in exchange for a cash payment representing the difference between $156.00 and the exercise price of each share of underlying common stock. Read SEC document
December 13, 2021 Filed Dec 15, 2021 20:40 UTC	Hill-Rom Holdings, Inc. HRC · Entity 132395	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	15,491	$52.89 Strike: $103.11	$819,318.99	Disclosure SEC source: 0001214659-21-013211 · marketforms-54634.xml · derivative · entry 3 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,491 shares Expires 2029-11-06 F4 · price: Pursuant to the Merger Agreement, these options, which provided for vesting in four equal installments beginning on November 6, 2020, were cancelled in exchange for a cash payment representing the difference between $156.00 and the exercise price of each share of underlying common stock. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, these options, which provided for vesting in four equal installments beginning on November 6, 2020, were cancelled in exchange for a cash payment representing the difference between $156.00 and the exercise price of each share of underlying common stock. Read SEC document
December 13, 2021 Filed Dec 15, 2021 20:40 UTC	Hill-Rom Holdings, Inc. HRC · Entity 132395	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	10,272	$57.24 Strike: $98.76	$587,969.28	Disclosure SEC source: 0001214659-21-013211 · marketforms-54634.xml · derivative · entry 2 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,272 shares Expires 2028-12-03 F3 · price: Pursuant to the Merger Agreement, these options, which provided for vesting in four equal installments beginning on December 3, 2019, were cancelled in exchange for a cash payment representing the difference between $156.00 and the exercise price of each share of underlying common stock. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, these options, which provided for vesting in four equal installments beginning on December 3, 2019, were cancelled in exchange for a cash payment representing the difference between $156.00 and the exercise price of each share of underlying common stock. Read SEC document
December 13, 2021 Filed Dec 15, 2021 20:40 UTC	Hill-Rom Holdings, Inc. HRC · Entity 132395	Disposition to issuerCommon Stock	14,039.759	Not disclosed	Not disclosed	Disclosure SEC source: 0001214659-21-013211 · marketforms-54634.xml · nonDerivative · entry 1 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Amount of securities beneficially owned at the end of the reporting period includes 718.759 shares held in the Hill-Rom Holdings, Inc. Employee Stock Purchase Plan. F2 · price: Disposed of pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter (the "Merger Agreement") in exchange for a cash payment of $156.00 per share of common stock. Read SEC document
December 06, 2021 Filed Dec 8, 2021 18:34 UTC	Hill-Rom Holdings, Inc. HRC · Entity 132395	Exercise / conversionRestricted Stock Units (12/03/2018) · Derivative	2,640	$0.00	$0.00	Disclosure SEC source: 0001214659-21-012902 · marketforms-54538.xml · derivative · entry 8 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,640 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: RSUs were granted on December 3, 2018 and vested 34% on December 4, 2019, 33% on December 4, 2020 and 33% on December 4, 2021. RSUs will automatically be converted into shares of common stock on the date indicated and are entitled to dividend equivalent rights which accrue on dividend record dates. F4 · derivative.expiration_date: RSUs were granted on December 3, 2018 and vested 34% on December 4, 2019, 33% on December 4, 2020 and 33% on December 4, 2021. RSUs will automatically be converted into shares of common stock on the date indicated and are entitled to dividend equivalent rights which accrue on dividend record dates. Read SEC document
December 06, 2021 Filed Dec 8, 2021 18:34 UTC	Hill-Rom Holdings, Inc. HRC · Entity 132395	Exercise / conversionRestricted Stock Units (12/03/2018) LTI · Derivative	992	$0.00	$0.00	Disclosure SEC source: 0001214659-21-012902 · marketforms-54538.xml · derivative · entry 7 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 992 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: RSUs were granted on December 3, 2018 and vested 34% on December 4, 2019, 33% on December 4, 2020 and 33% on December 4, 2021. RSUs will automatically be converted into shares of common stock on the date indicated and are entitled to dividend equivalent rights which accrue on dividend record dates. F4 · derivative.expiration_date: RSUs were granted on December 3, 2018 and vested 34% on December 4, 2019, 33% on December 4, 2020 and 33% on December 4, 2021. RSUs will automatically be converted into shares of common stock on the date indicated and are entitled to dividend equivalent rights which accrue on dividend record dates. Read SEC document
December 06, 2021 Filed Dec 8, 2021 18:34 UTC	Hill-Rom Holdings, Inc. HRC · Entity 132395	GiftCommon Stock	2,000	$0.00	$0.00	Disclosure SEC source: 0001214659-21-012902 · marketforms-54538.xml · nonDerivative · entry 5 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,321 Read SEC document
December 06, 2021 Filed Dec 8, 2021 18:34 UTC	Hill-Rom Holdings, Inc. HRC · Entity 132395	Tax withholdingCommon Stock	1,192	$155.73	$185,630.16	Disclosure SEC source: 0001214659-21-012902 · marketforms-54538.xml · nonDerivative · entry 4 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,321 F2 · kind: Reflects the reporting person's payment of minimum statutory tax obligations by withholding shares of Hill-Rom Holdings, Inc. common stock incident to the vesting of RSUs in accordance with Rule 16b-3. Read SEC document
December 06, 2021 Filed Dec 8, 2021 18:34 UTC	Hill-Rom Holdings, Inc. HRC · Entity 132395	Exercise / conversionCommon Stock	2,640	Not disclosed	Not disclosed	Disclosure SEC source: 0001214659-21-012902 · marketforms-54538.xml · nonDerivative · entry 3 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document
December 06, 2021 Filed Dec 8, 2021 18:34 UTC	Hill-Rom Holdings, Inc. HRC · Entity 132395	Tax withholdingCommon Stock	448	$155.73	$69,767.04	Disclosure SEC source: 0001214659-21-012902 · marketforms-54538.xml · nonDerivative · entry 2 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,873 F2 · kind: Reflects the reporting person's payment of minimum statutory tax obligations by withholding shares of Hill-Rom Holdings, Inc. common stock incident to the vesting of RSUs in accordance with Rule 16b-3. Read SEC document
December 06, 2021 Filed Dec 8, 2021 18:34 UTC	Hill-Rom Holdings, Inc. HRC · Entity 132395	Exercise / conversionCommon Stock	992	Not disclosed	Not disclosed	Disclosure SEC source: 0001214659-21-012902 · marketforms-54538.xml · nonDerivative · entry 1 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document
November 12, 2021 Filed Nov 16, 2021 20:15 UTC	Hill-Rom Holdings, Inc. HRC · Entity 132395	Exercise / conversionRestricted Stock Units (11/11/2020) · Derivative	1,557	$0.00	$0.00	Disclosure SEC source: 0001214659-21-011929 · marketforms-54274.xml · derivative · entry 4 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,989 Underlying: Common Stock · 1,557 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: RSUs were granted on November 11, 2020 and vested 34% on November 12, 2021; 33% will vest on November 12, 2022 and 33% will vest on November 12, 2023. RSUs will automatically be converted into shares of common stock on the date indicated and are entitled to dividend equivalent rights which accrue on dividend record dates. F4 · derivative.expiration_date: RSUs were granted on November 11, 2020 and vested 34% on November 12, 2021; 33% will vest on November 12, 2022 and 33% will vest on November 12, 2023. RSUs will automatically be converted into shares of common stock on the date indicated and are entitled to dividend equivalent rights which accrue on dividend record dates. Read SEC document
November 12, 2021 Filed Nov 16, 2021 20:15 UTC	Hill-Rom Holdings, Inc. HRC · Entity 132395	Tax withholdingCommon Stock	699	$155.11	$108,421.89	Disclosure SEC source: 0001214659-21-011929 · marketforms-54274.xml · nonDerivative · entry 2 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,329 F2 · kind: Reflects the reporting person's payment of minimum statutory tax obligations by withholding shares of Hill-Rom Holdings, Inc. common stock incident to the vesting of RSUs in accordance with Rule 16b-3. Read SEC document
November 12, 2021 Filed Nov 16, 2021 20:15 UTC	Hill-Rom Holdings, Inc. HRC · Entity 132395	Exercise / conversionCommon Stock	1,557	Not disclosed	Not disclosed	Disclosure SEC source: 0001214659-21-011929 · marketforms-54274.xml · nonDerivative · entry 1 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,028 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document
November 10, 2021 Filed Nov 12, 2021 17:30 UTC	Hill-Rom Holdings, Inc. HRC · Entity 132395	GrantRestricted Stock Units (11/10/2021) · Derivative	13,951	$0.00	$0.00	Disclosure SEC source: 0001214659-21-011623 · marketforms-54244.xml · derivative · entry 1 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,951 Underlying: Common Stock · 13,951 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: RSUs vest 34% on November 11, 2022, 33% on November 11, 2023 and 33% on November 11, 2024. RSUs will automatically be converted into shares of common stock on the date indicated and are entitled to dividend equivalent rights which accrue on dividend record dates. F2 · derivative.expiration_date: RSUs vest 34% on November 11, 2022, 33% on November 11, 2023 and 33% on November 11, 2024. RSUs will automatically be converted into shares of common stock on the date indicated and are entitled to dividend equivalent rights which accrue on dividend record dates. Read SEC document
November 08, 2021 Filed Nov 10, 2021 20:53 UTC	Hill-Rom Holdings, Inc. HRC · Entity 132395	Exercise / conversionRestricted Stock Units (11/06/2019) · Derivative	1,249	$0.00	$0.00	Disclosure SEC source: 0001214659-21-011436 · marketforms-54217.xml · derivative · entry 4 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,232.427 Underlying: Common Stock · 1,249 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: RSUs were granted on November 6, 2019 and vested 34% on November 7, 2020 and 33% on November 7, 2021; 33% will vest on November 7, 2022. RSUs will automatically be converted into shares of common stock on the date indicated and are entitled to dividend equivalent rights which accrue on dividend record dates. F4 · derivative.expiration_date: RSUs were granted on November 6, 2019 and vested 34% on November 7, 2020 and 33% on November 7, 2021; 33% will vest on November 7, 2022. RSUs will automatically be converted into shares of common stock on the date indicated and are entitled to dividend equivalent rights which accrue on dividend record dates. Read SEC document
November 08, 2021 Filed Nov 10, 2021 20:53 UTC	Hill-Rom Holdings, Inc. HRC · Entity 132395	Tax withholdingCommon Stock	561	$155.09	$87,005.49	Disclosure SEC source: 0001214659-21-011436 · marketforms-54217.xml · nonDerivative · entry 2 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,471 F2 · kind: Reflects the reporting person's payment of minimum statutory tax obligations by withholding shares of Hill-Rom Holdings, Inc. common stock incident to the vesting of RSUs in accordance with Rule 16b-3. Read SEC document
November 08, 2021 Filed Nov 10, 2021 20:53 UTC	Hill-Rom Holdings, Inc. HRC · Entity 132395	Exercise / conversionCommon Stock	1,249	Not disclosed	Not disclosed	Disclosure SEC source: 0001214659-21-011436 · marketforms-54217.xml · nonDerivative · entry 1 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document
November 01, 2021 Filed Nov 3, 2021 20:57 UTC	Hill-Rom Holdings, Inc. HRC · Entity 132395	Tax withholdingCommon Stock	3,102	$155.17	$481,337.34	Disclosure SEC source: 0001214659-21-011118 · marketforms-54159.xml · nonDerivative · entry 2 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,783 F2 · kind: Reflects the reporting person's payment of minimum statutory tax obligations by withholding shares of Hill-Rom Holdings, Inc. common stock incident to the vesting of performance restricted stock units in accordance with Rule 16b-3. Read SEC document
November 01, 2021 Filed Nov 3, 2021 20:57 UTC	Hill-Rom Holdings, Inc. HRC · Entity 132395	GrantCommon Stock	9,017	$0.00	$0.00	Disclosure SEC source: 0001214659-21-011118 · marketforms-54159.xml · nonDerivative · entry 1 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,885 F1 · kind: Reflects shares of common stock received upon vesting of performance based restricted stock awards granted in 2018 for the performance period ended September 30, 2021. Read SEC document
March 31, 2021 Filed Apr 1, 2021 21:01 UTC	Turning Point Therapeutics, Inc. TPTX · Entity 124461	GrantStock Option (right to buy) · Derivative	14,995	$0.00 Strike: $94.59	$0.00	Disclosure SEC source: 0001209191-21-024312 · doc4.xml · derivative · entry 1 Bodem Barbara W. · CIK 0001713893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,995 Underlying: Common Stock · 14,995 shares Expires 2031-03-30 F1 · derivative.exercise_date: The shares vest in a series of 36 successive equal monthly installments over the three-year period measured from the date of grant. Read SEC document
December 04, 2020 Filed Dec 7, 2020 16:01 UTC	Hill-Rom Holdings, Inc. HRC · Entity 132395	Exercise / conversionRestricted Stock Units (12/03/2018) · Derivative	2,616	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000047518-20-000150 · wf-form4_160737489333642.xml · derivative · entry 7 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,618.643 Underlying: Common Stock · 2,616 shares Expires 2021-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: Restricted stock units ("RSUs") were granted on December 3, 2018 and vested 34% on December 4, 2019 and 33% on December 4, 2020. The remaining 33% will vest on December 4, 2021. RSUs will automatically be converted into shares of common stock on the date indicated and are entitled to dividend equivalent rights which accrue on dividend record dates. F3 · derivative.expiration_date: Restricted stock units ("RSUs") were granted on December 3, 2018 and vested 34% on December 4, 2019 and 33% on December 4, 2020. The remaining 33% will vest on December 4, 2021. RSUs will automatically be converted into shares of common stock on the date indicated and are entitled to dividend equivalent rights which accrue on dividend record dates. Read SEC document
December 04, 2020 Filed Dec 7, 2020 16:01 UTC	Hill-Rom Holdings, Inc. HRC · Entity 132395	Exercise / conversionRestricted Stock Units (12/03/2018) LTI · Derivative	980	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000047518-20-000150 · wf-form4_160737489333642.xml · derivative · entry 6 Bodem Barbara W. · CIK 0001713893 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 983.122 Underlying: Common Stock · 980 shares Expires 2021-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: Restricted stock units ("RSUs") were granted on December 3, 2018 and vested 34% on December 4, 2019 and 33% on December 4, 2020. The remaining 33% will vest on December 4, 2021. RSUs will automatically be converted into shares of common stock on the date indicated and are entitled to dividend equivalent rights which accrue on dividend record dates. F3 · derivative.expiration_date: Restricted stock units ("RSUs") were granted on December 3, 2018 and vested 34% on December 4, 2019 and 33% on December 4, 2020. The remaining 33% will vest on December 4, 2021. RSUs will automatically be converted into shares of common stock on the date indicated and are entitled to dividend equivalent rights which accrue on dividend record dates. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.